Skip to main content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Detection bias may contribute to reduced prostate cancer risk in diabetes

PSA test

The reduced prostate cancer risk seen in men with diabetes may be partly explained by detection bias due to a lower biopsy rate following an elevated prostate-specific antigen test result, population-based study data show.

Different ADT combination therapies offer similar prostate cancer survival benefits

Prostate cancer medicines

Adding docetaxel, abiraterone acetate, enzalutamide, or apalutamide to androgen deprivation therapy  significantly improves survival for men with metastatic hormone-sensitive prostate cancer, with little difference between each drug, a network meta-analysis shows.

Network meta-analysis identifies best clinical choices for EGFR-mutated NSCLC


Osimertinib and gefitinib plus pemetrexed-based chemotherapy offer the best survival outcomes for patients with advanced EGFR-mutated non-small-cell lung cancer compared with other first-line treatments, shows a network meta-analysis of randomized trials.

Latest headlines

13-11-2019 | Checkpoint blockade | News

HLA-I evolutionary divergence linked to ICI response in cancer

HLA class I evolutionary divergence is associated with response to immune checkpoint inhibitor treatment in people with cancer, show data published in Nature Medicine.

12-11-2019 | Lung cancer | News

Lung cancer undertreatment common in USA, regardless of clinical subtype

Between 2010 and 2014, more than a third of lung cancer patients in the USA received less intensive treatment than recommended, or indeed no treatment at all, shows an analysis of data from the US National Cancer Database.

11-11-2019 | Checkpoint blockade | News

‘No justification’ for HIV exclusion from ICI trials

Researchers highlight the “almost universal exclusion” of people living with HIV from clinical trials of immune checkpoint inhibitor therapies despite malignancy being the leading cause of morbidity and mortality in this population.

In depth

31-10-2019 | Renal cell carcinoma | At a glance | Article

At a glance: The JAVELIN RCC trials

A quick-access guide to the JAVELIN trials of the anti-PD-L1 agent avelumab in the renal cell carcinoma setting.

26-09-2019 | Renal cell carcinoma | At a glance | Article

At a glance: The KEYNOTE RCC trials

A quick-reference guide to the KEYNOTE clinical trials evaluating the immune checkpoint inhibitor pembrolizumab in patients with renal cell carcinoma.

28-02-2019 | Lung cancer | At a glance | Article

At a glance: CheckMate lung cancer trials

Here we round up the CheckMate trials evaluating the PD-1 inhibitor nivolumab in non-small-cell lung cancer and small-cell lung cancer.

Image Credits